Literature DB >> 3154312

Comparative effects of prolonged therapy with four calcium ion antagonists (diltiazem, nicardipine, tiapamil and verapamil) in patients with chronic stable angina pectoris.

N S Khurmi1, E B Raftery.   

Abstract

The comparative effects of prolonged chronic therapy with diltiazem, nicardipine, tiapamil and verapamil on exercise tolerance, ST-segment changes and heart rate were examined in 63 patients with established chronic stable angina pectoris. Multistage computer-assisted symptom-limited treadmill exercise tests were performed after 2 weeks of placebo ("baseline") and then after 4 months of open-label chronic drug therapy. Diltiazem improved the exercise duration by 95% (p less than 0.001), nicardipine by 45% (p less than 0.001), tiapamil by 69% and verapamil by 79% (p less than 0.001). Maximal ST-segment depression was not altered by any of the drugs, but time to the development of 1 mm ST-segment depression was significantly improved in all cases. Diltiazem and verapamil reduced the heart rate at rest significantly by 6 and 8 beats/minute, respectively, whereas nicardipine increased it by 10 beats/minute (p less than 0.02), and tiapamil did not produce any significant change. Maximal heart rate at the peak of exercise was increased by 14% with nicardipine (p less than 0.001) and 6% with verapamil (p less than 0.05), whereas diltiazem and tiapamil did not produce any appreciable effect. The rate-pressure product at the peak of exercise remained unaltered with diltiazem, tiapamil and verapamil, but with nicardipine it increased significantly to 222 +/- 10 units from a baseline of 175 +/- 6 units with placebo.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3154312     DOI: 10.1007/bf02125837

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  32 in total

1.  Letter: Grading of angina pectoris.

Authors:  L Campeau
Journal:  Circulation       Date:  1976-09       Impact factor: 29.690

Review 2.  Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle.

Authors:  A Fleckenstein
Journal:  Annu Rev Pharmacol Toxicol       Date:  1977       Impact factor: 13.820

3.  Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status.

Authors:  D R Rosing; K M Kent; B J Maron; S E Epstein
Journal:  Circulation       Date:  1979-12       Impact factor: 29.690

4.  Comparison of diltiazem at two dose levels with propranolol for treatment of stable angina pectoris.

Authors:  M J O'Hara; N S Khurmi; M J Bowles; V B Subramanian; C J Doré; E B Raftery
Journal:  Am J Cardiol       Date:  1984-09-01       Impact factor: 2.778

Review 5.  Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem.

Authors:  P D Henry
Journal:  Am J Cardiol       Date:  1980-12-01       Impact factor: 2.778

6.  Effect of propranolol on indices of intermittent myocardial ischemia, assessed by exercise testing and ambulatory ST-segment monitoring.

Authors:  N S Khurmi; M J Bowles; M J O'Hara; E B Raftery
Journal:  Clin Cardiol       Date:  1986-08       Impact factor: 2.882

7.  The 24-hour ambulatory blood pressure profile with verapamil.

Authors:  B A Gould; S Mann; H Kieso; V B Subramanian; E B Raftery
Journal:  Circulation       Date:  1982-01       Impact factor: 29.690

8.  Randomized double-blind placebo-controlled comparison of nicardipine and nifedipine in patients with chronic stable angina pectoris.

Authors:  M J Bowles; N S Khurmi; M J O'Hara; E B Raftery
Journal:  Chest       Date:  1986-02       Impact factor: 9.410

9.  Increased exercise tolerance after oral diltiazem, a calcium antagonist, in angina pectoris.

Authors:  Y Koiwaya; M Nakamura; A Mitsutake; S Tanaka; A Takeshita
Journal:  Am Heart J       Date:  1981-02       Impact factor: 4.749

10.  Double-blind randomized crossover trial of verapamil and propranolol in chronic stable angina.

Authors:  M J Bowles; V Bala Subramanian; A B Davies; E B Raftery
Journal:  Am Heart J       Date:  1983-12       Impact factor: 4.749

View more
  2 in total

Review 1.  Calcium channel antagonists. Part V: Second-generation agents.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-07       Impact factor: 3.727

Review 2.  Calcium channel antagonists. Part II: Use and comparative properties of the three prototypical calcium antagonists in ischemic heart disease, including recommendations based on an analysis of 41 trials.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-01       Impact factor: 3.727

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.